MedPath

Prospective study of TS-1 / CPT-11 plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC02)

Not Applicable
Conditions
Breast Cancer
Registration Number
JPRN-UMIN000008647
Lead Sponsor
Kurume University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1.With contraindicate TS-1, CPT-11 and Trastuzumab 2.With active double cancer 3.With uncontrolled diabetes 4.Heart failure with clinically problem 5.Symptomatic brain metastasis 6.With mental disorder which become problem on clinical practice 7.With uncontrolled hypertension 8.Physician judged improper to entry this trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression free survival(PFS)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath